

Anti-B7-H1/PD-L1/CD274 Antibody (Durvalumab)

Introduction

Durvalumab (anti-PD-L1) is an IgG1κ monoclonal antibody that inhibits the interaction between PD-L1 and PD-1/CD80 (B7.1).

Product parameters

Alternative Names	C134, MEDI4736
Target Accession	Q9NZQ7
Target	B7-H1 / PD-L1 / CD274
CAS number	1428935-60-7
Molecular Weight	146.32 kDa
Host	CHO
Reactivity	Human, Mouse, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human PD-L1 His at 2 ug/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (Durvalumab), EC50=0.03756 ug/mL
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

